The ability to sequence patient DNA has led to an explosion in the reports of mutations for a number of diseases. Frequently, published reports include in silico predictions of the probability that the mutations are disease-associated. The question asked here is how well these in silico methods predict the effects of new mutations, i.e., mutations not included in the dataset(s) used for training and testing the in silico method. To address this question, we examined mutations associated, or potentially associated, with Morquio A (MPS IVA), a rare, autosomal recessive lysosomal storage disorder (LSD) caused by a deficiency of lysosomal enzyme N-acetylgalactosamine-6-sulfatase (GALNS). In the severe form of the disease, life expectancy is less than 30 years. More than 200 unique missense mutations have been identified in the GALNS gene, with effects ranging from no change in function (wild-type) to significant reduction in functional effect (severe forms of the disease). Using GALNS as the model gene, we evaluated the ability of select publicly available in silico methods to predict the functional effects of these mutations. Specifically, the predictions of GALNS mutations on enzyme activity were evaluated and compared to both published and unpublished Morquio A mutations. Functional effects for unpublished Morquio A mutations were determined by measuring the enzyme activity of cells transiently transfected with mutant gene cassettes. Although some of the in silico packages perform better than others, they may not be used either individually or in combination to predict with any level of certainty whether or not any particular mutation is deleterious. Our results strongly suggest that testing enzyme activity is still required to determine the functional impact of a specific mutation.
","abstract_html":"<p>The ability to sequence patient DNA has led to an explosion in the reports of mutations for a number of diseases. Frequently, published reports include in silico predictions of the probability that the mutations are disease-associated. The question asked here is how well these in silico methods predict the effects of new mutations, i.e., mutations not included in the dataset(s) used for training and testing the in silico method. To address this question, we examined mutations associated, or potentially associated, with Morquio A (MPS IVA), a rare, autosomal recessive lysosomal storage disorder (LSD) caused by a deficiency of lysosomal enzyme N-acetylgalactosamine-6-sulfatase (GALNS). In the severe form of the disease, life expectancy is less than 30 years. More than 200 unique missense mutations have been identified in the GALNS gene, with effects ranging from no change in function (wild-type) to significant reduction in functional effect (severe forms of the disease). Using GALNS as the model gene, we evaluated the ability of select publicly available in silico methods to predict the functional effects of these mutations. Specifically, the predictions of GALNS mutations on enzyme activity were evaluated and compared to both published and unpublished Morquio A mutations. Functional effects for unpublished Morquio A mutations were determined by measuring the enzyme activity of cells transiently transfected with mutant gene cassettes. Although some of the in silico packages perform better than others, they may not be used either individually or in combination to predict with any level of certainty whether or not any particular mutation is deleterious. Our results strongly suggest that testing enzyme activity is still required to determine the functional impact of a specific mutation.</p>","abstract_has_math":false,"creators":["Davidson, Kathryn"],"institution":null,"degree_name":"Master of Science","degree_level":"Master's Thesis","degree_discipline":"Biological Sciences","degree_department":null,"school":null,"contributors":["Jonathan H. LeBowitz, PhD","Maggie Louie, PhD"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-05-01T07:00:00Z","date_published":"2014-05-01T07:00:00Z","updated_at":"2026-07-24T02:04:28Z","subjects":["DNA Testing","DNA Mutations","Genetics and Genomics","Laboratory and Basic Science Research","Life Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://scholar.dominican.edu/masters-theses/53","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Jonathan H. LeBowitz, PhD","Maggie Louie, PhD"]},{"key":"dc:creator","label":"Author","values":["Davidson, Kathryn"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["1970-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biological Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Master's Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["DNA Testing","DNA Mutations","Genetics and Genomics","Laboratory and Basic Science Research","Life Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://scholar.dominican.edu/masters-theses/53"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The ability to sequence patient DNA has led to an explosion in the reports of mutations for a number of diseases. Frequently, published reports include in silico predictions of the probability that the mutations are disease-associated. The question asked here is how well these in silico methods predict the effects of new mutations, i.e., mutations not included in the dataset(s) used for training and testing the in silico method. To address this question, we examined mutations associated, or potentially associated, with Morquio A (MPS IVA), a rare, autosomal recessive lysosomal storage disorder (LSD) caused by a deficiency of lysosomal enzyme N-acetylgalactosamine-6-sulfatase (GALNS). In the severe form of the disease, life expectancy is less than 30 years. More than 200 unique missense mutations have been identified in the GALNS gene, with effects ranging from no change in function (wild-type) to significant reduction in functional effect (severe forms of the disease). Using GALNS as the model gene, we evaluated the ability of select publicly available in silico methods to predict the functional effects of these mutations. Specifically, the predictions of GALNS mutations on enzyme activity were evaluated and compared to both published and unpublished Morquio A mutations. Functional effects for unpublished Morquio A mutations were determined by measuring the enzyme activity of cells transiently transfected with mutant gene cassettes. Although some of the in silico packages perform better than others, they may not be used either individually or in combination to predict with any level of certainty whether or not any particular mutation is deleterious. Our results strongly suggest that testing enzyme activity is still required to determine the functional impact of a specific mutation.
"]},{"key":"dc:title","label":"Title","values":["Evaluation of Select Publicly Available in Silico Methods for Predicting Functional Effects of Missense Mutations in the GALNS Gene"]}]}],"canonical_facts":{"dc:contributor":["Jonathan H. LeBowitz, PhD","Maggie Louie, PhD"],"dc:creator":["Davidson, Kathryn"],"dc:date.available":["1970-01-01T08:00:00Z"],"dc:description.abstract":["The ability to sequence patient DNA has led to an explosion in the reports of mutations for a number of diseases. Frequently, published reports include in silico predictions of the probability that the mutations are disease-associated. The question asked here is how well these in silico methods predict the effects of new mutations, i.e., mutations not included in the dataset(s) used for training and testing the in silico method. To address this question, we examined mutations associated, or potentially associated, with Morquio A (MPS IVA), a rare, autosomal recessive lysosomal storage disorder (LSD) caused by a deficiency of lysosomal enzyme N-acetylgalactosamine-6-sulfatase (GALNS). In the severe form of the disease, life expectancy is less than 30 years. More than 200 unique missense mutations have been identified in the GALNS gene, with effects ranging from no change in function (wild-type) to significant reduction in functional effect (severe forms of the disease). Using GALNS as the model gene, we evaluated the ability of select publicly available in silico methods to predict the functional effects of these mutations. Specifically, the predictions of GALNS mutations on enzyme activity were evaluated and compared to both published and unpublished Morquio A mutations. Functional effects for unpublished Morquio A mutations were determined by measuring the enzyme activity of cells transiently transfected with mutant gene cassettes. Although some of the in silico packages perform better than others, they may not be used either individually or in combination to predict with any level of certainty whether or not any particular mutation is deleterious. Our results strongly suggest that testing enzyme activity is still required to determine the functional impact of a specific mutation.
"],"dc:identifier":["https://scholar.dominican.edu/masters-theses/53"],"dc:subject":["DNA Testing","DNA Mutations","Genetics and Genomics","Laboratory and Basic Science Research","Life Sciences"],"dc:title":["Evaluation of Select Publicly Available in Silico Methods for Predicting Functional Effects of Missense Mutations in the GALNS Gene"],"thesis:degree_discipline":["Biological Sciences"],"thesis:degree_level":["Master's Thesis"],"thesis:degree_name":["Master of Science"]},"updated_at":"2026-07-24T02:04:28Z"}